Publications by authors named "Marimee Godbout-Parent"
Article Synopsis
- - The study focuses on understanding what influences healthcare professionals' comfort when prescribing medicatioons for chronic pain, with a goal to improve education and training in this area.
- - A survey of 207 licensed physicians, pharmacists, and nurse practitioners in Quebec showed that over half reported a comfort level below 6 out of 10 for managing chronic pain prescriptions, with significant differences among the professions.
- - Factors that increased comfort included being a pharmacist and engaging in continuous education, while lower comfort levels were linked to being a nurse practitioner and having less experience, indicating that these disparities can impact patient care quality.
The COVID-19 pandemic has brought its fair share of consequences. To control the transmission of the virus, several public health restrictions were put in place. While these restrictions had beneficial effects on transmission, they added to the pre-existing physical, psychosocial, and financial burdens associated with chronic pain, and made existing treatment gaps, challenges, and inequities worse.
View Article and Find Full Text PDFBackground: Pharmacological management of fibromyalgia is complex. Chronic pain management is characterized by off-label prescribing and use, multimorbidity, and polypharmacy.
Aims: This study aimed to describe pain medications use and perceived risk among people living with fibromyalgia and compare this use to evidence-based recommendations.
To quantify risks associated with drug utilization in the real world for the treatment of chronic pain (CP), an index called the Medication Quantification Scale (MQS) was developed in 1992 in the United States and last updated in 2003. This study aimed to update, adapt to the contemporary Canadian context, and validate a revised version of the MQS (the MQS-4.0).
View Article and Find Full Text PDFTreatment of chronic pain should be multimodal and include pharmacological, physical, and psychological treatments. However, because various barriers to physical and psychological treatments (PPTs) exist, a better understanding of biopsychosocial factors leading to their use is relevant. This study aimed to explore the association between gender identity, gender-stereotyped personality traits, and the use of PPTs in chronic pain management.
View Article and Find Full Text PDFArticle Synopsis
- Medical cannabis has been legal in Canada since 2001, with recreational use legalized in 2018, leading to increased accessibility for users.
- A study analyzed data from 1,935 adults with chronic pain (CP) in Quebec to estimate cannabis use prevalence and its relationship to age, finding 30.1% used cannabis for pain management, with higher use among younger adults.
- The results suggest that cannabis is a popular option for CP treatment, especially for younger individuals, highlighting the need for better information on its safety and clinical guidance for users.
Objectives: Understanding gender differences in chronic pain (CP) outcome research is essential to optimal treatment delivery. This study explored the associations between gender identity, gender roles, and the number of non-life-threatening pain medication adverse effects reported as severe by people living with CP.
Methods: The analyses were conducted using the COPE Cohort, a dataset generated through a web-based recruitment of adults with CP.
Introduction: Multimodal treatment is recognized as the optimal paradigm for the management of chronic pain (CP). Careful balance between pharmacological and physical/psychological approaches is thus desirable but can be easily disrupted.
Objectives: This study aimed at exploring the impact of the COVID-19 pandemic on pharmacological and physical/psychological treatments of CP.